Published in Health Business Week, January 12th, 2007
The urine-based test, which measures levels of a protein-based biomarker for Alzheimer disease, is available to physicians in major markets, including Europe and the United States. A recent article in The Wall Street Journal described competing tests in this area that employ measuring multiple protein biomarkers and quoted a conservative estimate that these possible competitors were three to five years away from the clinic.
"Experience has shown that tests which require...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.